Eli Lilly (LLY) emerges among the top performers in Big Pharma in 2024 with obesity drug success, while Novo Nordisk (NVO) ...

Although Novo will still make a mind-blowing amount of money from its existing obesity drugs in the coming years (its ...

Given Novo Nordisk's long-term prospects, its recent share price correction offers investors a great buying opportunity. If ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...